Subsequent to the release of positive phase 3 trial results, vistagen provides corporate update and reports fiscal 2024 first quarter financial results

South san francisco, calif.--(business wire)---- $vtgn #mentalhealth--vistagen (nasdaq: vtgn), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (cns) disorders, today provided a corporate update and reported financial results for its fiscal year 2024 first quarter ended june 30, 2023. "the positive outcome of our palisade-2 study demonstrated that fasedienol significantly reduced the mean subjec.
VTGN Ratings Summary
VTGN Quant Ranking